LifeSci Advisors, LLC’s Post

In an interim analysis presented at #ESMOBreast24, first-line treatment with the combination of the PD-L1 inhibitor atezolizumab and sacituzumab govitecan showed a higher objective response rate compared to control in patients with previously untreated PD-L1 positive locally advanced or metastatic triple-negative breast cancer (#TNBC). 👇To learn more about this topic, read the #ESMODailyReporter https://ow.ly/FPVv50RQJpZ

ctDNA proves to be a valuable marker for guiding adjuvant chemotherapy decisions in CRC patients - Yüksel ÜRÜN Pashtoon Kasi American Society of Clinical Oncology (ASCO) Weill Cornell Medicine https://lnkd.in/eXyMNTdM #CancerResearch #PrecisionMedicine #ASCOGI24 #ASCOGI2024 #oncology #oncodaily #cancer #ctDNA

🔬 Insights from ASCO 2024! Dr Paolo Tarantino (Dana-Farber Institute) and Dr Elisa Agostinetto (Institut Jules Bordet) discuss the results of a real-world study of trastuzumab deruxtecan in metastatic breast cancer. The study shows significant efficacy in HER2+ patients but reveals a shorter PFS compared to clinical trials. Explore the implications for clinical practice and patient safety. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #HER2

Join us on March 20th for a profound conversation featuring colorectal cancer survivor Eden Stotsky-Himelfarb and renowned oncology expert Dr. Paul Celano. We are in the middle of Colorectal Awareness Month, and sharing this event with a friend might find it helpful. Gain unique insights into colorectal cancer from both a patient's perspective and a medical professional's expertise. #ColorectalCancerAwareness2024 #ScreenSaveLives #FightColorectalCancer #EarlyDetectionMatters #ColorectalCancerAwareness202 #ScreenSaveLives  #FightColorectalCancer #EarlyDetectionMatters

With over 19,000 new cases each year and a 5-year survival rate below 50%, functional precision oncology for ovarian cancer is essential. Our 3D Predict™ test can be used to personalize chemotherapy for effective first-line treatments, ensuring each patient gets care tailored to their unique needs. Learn more: bit.ly/3SJjrxy #Kiyatec #3DPredict #PrecisionOncology #OvarianCancer

Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches 👇 Targeted Oncology provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions. Read more below 🔗 https://lnkd.in/eFMaB3g5

Key Takeaways on mBC and eBC: Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes. #finance #pharmacy #lifesciences

📷 We're live from #ESMO2024 in Barcelona! The conference has just kicked off and the Medimix team is here to capture all the latest insights and breakthroughs in cancer research. Make sure to keep an 👀 on both our socials and your inbox for live updates from the conference in the coming days. We look forward to sharing key takeaways that could impact the future of oncology treatments. #MediMix #Oncology #CancerResearch #ConferenceUpdates

Join us on March 20th for a profound conversation featuring colorectal cancer survivor Eden Stotsky-Himelfarb and renowned oncology expert Dr. Paul Celano. We are in the middle of Colorectal Awareness Month, and sharing this event with a friend might find it helpful. Gain unique insights into colorectal cancer from both a patient's perspective and a medical professional's expertise. #ColorectalCancerAwareness2024  #ScreenSaveLives #FightColorectalCancer #EarlyDetectionMatters #ColorectalCancerAwareness202 #ScreenSaveLives #FightColorectalCancer #EarlyDetectionMatters

Last week, our CEO Ben Zeskind, Ph.D. sat down with Caroline Hopkins at Precision Oncology News, to discuss the recent progress with our lead product candidate, IMM-1-104. From IMM-1-104's fast-track designation for patients with pancreatic cancer who have failed one line of treatment, to dosing our first patient in the Phase 2 portion of the ongoing IMM-1-104 Phase 1/2a clinical trial, to reporting positive preliminary data from the Phase 1 portion of that trial Read more about our differentiated approach to cancer research and next steps with IMM-1-104.https://buff.ly/4cvtRd2